Dual Therapy Holds Its Own in Treatment-Naive HIV
MONTREAL — A two-drug combination using a generic formulation of the protease inhibitor darunavir/ritonavir plus lamivudine appeared to control HIV as well as the same combination with added tenofovir, according to results of the phase IV ANDES trial reported here. In the intention-to-treat analysis, 91% patients on the dual therapy achieved undetectable viral loads using […]
Intranasal Zavegepant Shows Promise in Acute Migraine
Zavegepant, an investigational nasal spray formulation of a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, met its co-primary endpoints in a phase III randomized placebo-controlled trial of acute migraine. On both primary endpoints — 2-hour pain freedom (23.6% vs 14.9%, P<0.0001) and 2-hour freedom from most bothersome symptom (39.6% vs 31.1%, P=0.0012) — zavegepant was […]